According to a GlobalData survey, 35% of pharmaceutical industry professionals believe that the COVID-19 pandemic has speeded up digital transformation in the pharmaceutical industry by more than five years. Industry experts believe that apart from virtual interactions, technology has helped Indian Pharma in training and connecting doctors with global experts for knowledge sharing and this trend is poised to continue in the years to come as well. However, there are new pressure points building for the pharma industry now. This is largely triggered by the rise in price of raw material and API (active pharmaceutical ingredients or drug ingredients) apart from snarled supply chain. According to IDMA, industry has been facing a huge cost escalation due to imported raw materials and excipients - in some cases a very high increase in prices. While this is a challenge the Indian pharma has to deal with at the moment, the key ask of the industry is to be able to move from being the pharmacy of the world to emerging as an innovation hub. The FE Pharma Summit will bring together key stakeholders, to discuss what the industry needs to do to progress on this journey and what role can the government play to be an enabler. Also, being discussed, would be the role that technology can play in this. How do they look at the advances in drug discovery, nano technology and other areas and get the thought leaders to debate on finding effective and sustainable development of the industry. Some argue that sustainable manufacturing or green manufacturing may be one way to deal with competition from China. Finally, there is the aspect of the ever-changing regulatory scenario. What some of the newer provisions could mean for the industry and the way ahead.